Navigation Links
Melanoma drug revs immune cells but cancer cells ignore it
Date:9/2/2007

COLUMBUS , Ohio A new study shows that an important drug used in the treatment of malignant melanoma has little effect on the melanoma cells themselves. Instead, it activates immune-system cells to fight the disease.

The drug, called interferon alpha (IFNa), is used to clean up microscopic tumor cells that may remain in the body following surgery for the disease. It is the only drug approved for this purpose.

Researchers say that these findings underscore the need to develop ways to make melanoma cells more vulnerable to the drug, or to overcome the block within the cells that prevents them from responding to it.

The study showed that melanoma cells taken directly from patients, as well as those grown in the laboratory, respond poorly to IFNa, even when the drug is given at very high doses, while immune cells respond well to the same substance.

The study, led by researchers with the Ohio State University Comprehensive Cancer Center, is published in the journal Clinical Cancer Research.

IFNa is effective in only 10 to 20 percent of patients, but it's the best therapy available for these patients, and no therapies on the horizon have been proven any more effective, says principal investigator William E. Carson, III, professor of surgery and a melanoma specialist at Ohio State's James Cancer Hospital and Solove Research Institute.

It is critical that we understand exactly how this drug works and learn how to improve its effectiveness.

IFNa is an immune-system hormone made by the body to help other immune cells recognize and destroy developing tumors. As a drug, the substance is used to treat melanoma and other cancers.

Formerly, it was thought that IFNa acted directly on melanoma-tumor cells to stop their growth. But earlier research by Carson's laboratory and others suggested that the drug has a greater effect on the immune system.

The present study confirms that earlier work, says first author Gregory B. Lesinski, a research assistant professor in the department of molecular virology, immunology and medical genetics. The new findings are significant because they confirm that the immune system, and not the tumor cell, is the primary target of IFNa.

We show for the first time that even normal melanocytes are inherently less responsive to IFNa compared to immune cells. Melanocytes are the normal cells that, when cancerous, cause melanoma.

Some unknown factor in melanoma cells seems to turn down their response to IFNa, Lesinski explains. We are now trying to understand what that factor might be.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
Source:Eurekalert

Related medicine news :

1. UV Radiation induces Melanoma
2. Reduction in melanoma death rate
3. Latest device for identifying Melanomas
4. Specialist surgeon not imperative in melanoma
5. Tumour marker for melanoma found
6. Melanoma caused by low DNA repair capacity
7. Hope for First New Melanoma Treatment in Decades
8. Turmeric Found To Slow Down Melanoma Growth
9. Gene in Melanomas
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Skin Cancer History Puts Post-menopausal White Women At Risk For Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: